Silymarin's Advantage on Graft Effectiveness
Launched by UNIVERSITY HOSPITAL, MARTIN · Jan 24, 2025
Trial Information
Current as of July 01, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • First or second kidney transplant recipient
- • Deceased or living donor kidney transplant
- * Patients receiving standard immunosuppression regimen:
- • Tacrolimus or cyclosporine + Mycophenolate mofetil + Corticosteroids
- • Body Mass Index (BMI) 18-35 kg/m²
- • Willingness to provide informed consent
- • Ability to understand and comply with study procedures
- • Stable medical condition without significant comorbidities
- Exclusion Criteria:
- • Multi-organ transplant recipients
- • Recipients of ABO-incompatible or highly sensitized transplants
- • Active infectious complications at the time of transplantation: HIV, Active hepatitis B or C, Active cytomegalovirus (CMV) infection
- • Patients with known liver disease: Cirrhosis, Active hepatitis, ALT or AST \> 2.5 times the upper limit of normal
- • Significant cardiovascular disease: Recent myocardial infarction (within 6 months), Unstable angina, Severe heart failure (NYHA Class III or IV)
- • Malignancy within the past 5 years (except successfully treated non-melanoma skin cancer)
- • Current or recent (within 30 days) participation in another clinical trial
- • Pregnancy or planned pregnancy during the study period
- • Known allergy or hypersensitivity to silymarin or milk thistle
- * Patients taking medications with significant interactions with silymarin:
- • Anticoagulants, Cytochrome P450 enzyme modulators
- • Psychiatric conditions that may interfere with study compliance
- • Uncontrolled diabetes mellitus (HbA1c \> 8.5%)
- • History of non-compliance with medical treatment
- • Patients with known genetic disorders affecting drug metabolism
About University Hospital, Martin
University Hospital Martin is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical trials. With a commitment to patient-centered care and cutting-edge medical practices, the hospital collaborates with a diverse array of researchers and healthcare professionals to explore new therapeutic approaches and improve patient outcomes. Its state-of-the-art facilities and multidisciplinary teams enable the rigorous evaluation of novel treatments, contributing to the global body of medical knowledge while enhancing the quality of care provided to the community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Martin, , Slovakia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported